Matches in SemOpenAlex for { <https://semopenalex.org/work/W1820981194> ?p ?o ?g. }
- W1820981194 endingPage "7" @default.
- W1820981194 startingPage "1211" @default.
- W1820981194 abstract "Forty-six previously untreated patients with advanced breast cancer were eligible for the present randomised phase I study. It aimed to evaluate the toxicity and activity of a therapeutic sequence with epirubicin on day 1 followed by paclitaxel on day 2 (sequence A) or the reverse sequence, ie., paclitaxel on day 1 followed by epirubicin on day 2 (sequence B). The starting doses of epirubicin and paclitaxel, administered either according to sequence A or B, (level 1 cohort) were 90 mg/m2 and 175 mg/m2, respectively. Per cohort of 3 patients, the dose of paclitaxel was increased by 25 mg/m2 (levels 2 and 4) and of epirubicin by 10 mg/m2 (levels 3 and 5). Treatment was repeated with 3-week intervals. The maximal tolerated dose (MTD) was achieved at level 1 in sequence B (paclitaxel first) and level 3 (epirubicin 100 mg/m2 followed by paclitaxel 200 mg m2) in sequence A. Dose limiting toxicity (DLT) was neutropenia (+/- febrile) in both sequences. Cardiac events occurred in 28% of the patients; significant decrease in left ventricular ejection function (LVEF) was observed in 8/33 and in 2/13 patients in sequence A and B, respectively. This was associated with 5 and 1 cardiac heart failure (CHF), respectively. In 43 evaluable patients, 10 CR and 25 PR were observed (overall response rate 81%). In the 20 patients with locally advanced disease (LABC), the respective numbers were 7 CR and 11 PR; in the 23 metastatic (MBC) patients, 3 CR and 14 PR were recorded. The median survival of the both groups was not reached at 33 + months. In conclusion , the combination of epirubicin and paclitaxel has significant activity in breast cancer. The recommended sequence of both drugs in combination therapy, mainly to avoid neutropenia, is epirubicin day 1 followed by paclitaxel on day 2. Cardiac toxicity remains problematic in either sequence of administration." @default.
- W1820981194 created "2016-06-24" @default.
- W1820981194 creator A5015762135 @default.
- W1820981194 creator A5019631884 @default.
- W1820981194 creator A5031036197 @default.
- W1820981194 creator A5032818174 @default.
- W1820981194 creator A5058912347 @default.
- W1820981194 creator A5071675004 @default.
- W1820981194 creator A5077858358 @default.
- W1820981194 creator A5081661047 @default.
- W1820981194 creator A5088780624 @default.
- W1820981194 date "2005-05-04" @default.
- W1820981194 modified "2023-09-23" @default.
- W1820981194 title "Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial." @default.
- W1820981194 cites W1526183483 @default.
- W1820981194 cites W1923449517 @default.
- W1820981194 cites W1945178661 @default.
- W1820981194 cites W1960713055 @default.
- W1820981194 cites W1966805077 @default.
- W1820981194 cites W1975402824 @default.
- W1820981194 cites W2003420178 @default.
- W1820981194 cites W2008766841 @default.
- W1820981194 cites W2017167820 @default.
- W1820981194 cites W2035928588 @default.
- W1820981194 cites W2056435407 @default.
- W1820981194 cites W2065425187 @default.
- W1820981194 cites W2065937518 @default.
- W1820981194 cites W2089887845 @default.
- W1820981194 cites W2108028042 @default.
- W1820981194 cites W2119527917 @default.
- W1820981194 cites W2130344873 @default.
- W1820981194 cites W2133243551 @default.
- W1820981194 cites W2137373373 @default.
- W1820981194 cites W2155481114 @default.
- W1820981194 cites W2156836759 @default.
- W1820981194 cites W2186536638 @default.
- W1820981194 cites W2203687533 @default.
- W1820981194 cites W2228702773 @default.
- W1820981194 cites W2242824667 @default.
- W1820981194 cites W2268597691 @default.
- W1820981194 cites W2270235662 @default.
- W1820981194 cites W2334195749 @default.
- W1820981194 cites W2410755836 @default.
- W1820981194 cites W2417739967 @default.
- W1820981194 cites W2422454534 @default.
- W1820981194 cites W25774907 @default.
- W1820981194 cites W2751866160 @default.
- W1820981194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15865068" @default.
- W1820981194 hasPublicationYear "2005" @default.
- W1820981194 type Work @default.
- W1820981194 sameAs 1820981194 @default.
- W1820981194 citedByCount "3" @default.
- W1820981194 countsByYear W18209811942019 @default.
- W1820981194 crossrefType "journal-article" @default.
- W1820981194 hasAuthorship W1820981194A5015762135 @default.
- W1820981194 hasAuthorship W1820981194A5019631884 @default.
- W1820981194 hasAuthorship W1820981194A5031036197 @default.
- W1820981194 hasAuthorship W1820981194A5032818174 @default.
- W1820981194 hasAuthorship W1820981194A5058912347 @default.
- W1820981194 hasAuthorship W1820981194A5071675004 @default.
- W1820981194 hasAuthorship W1820981194A5077858358 @default.
- W1820981194 hasAuthorship W1820981194A5081661047 @default.
- W1820981194 hasAuthorship W1820981194A5088780624 @default.
- W1820981194 hasConcept C121608353 @default.
- W1820981194 hasConcept C126322002 @default.
- W1820981194 hasConcept C141071460 @default.
- W1820981194 hasConcept C2775930923 @default.
- W1820981194 hasConcept C2776694085 @default.
- W1820981194 hasConcept C2777292972 @default.
- W1820981194 hasConcept C2778198053 @default.
- W1820981194 hasConcept C2780835546 @default.
- W1820981194 hasConcept C530470458 @default.
- W1820981194 hasConcept C71924100 @default.
- W1820981194 hasConcept C72563966 @default.
- W1820981194 hasConcept C78085059 @default.
- W1820981194 hasConcept C90924648 @default.
- W1820981194 hasConceptScore W1820981194C121608353 @default.
- W1820981194 hasConceptScore W1820981194C126322002 @default.
- W1820981194 hasConceptScore W1820981194C141071460 @default.
- W1820981194 hasConceptScore W1820981194C2775930923 @default.
- W1820981194 hasConceptScore W1820981194C2776694085 @default.
- W1820981194 hasConceptScore W1820981194C2777292972 @default.
- W1820981194 hasConceptScore W1820981194C2778198053 @default.
- W1820981194 hasConceptScore W1820981194C2780835546 @default.
- W1820981194 hasConceptScore W1820981194C530470458 @default.
- W1820981194 hasConceptScore W1820981194C71924100 @default.
- W1820981194 hasConceptScore W1820981194C72563966 @default.
- W1820981194 hasConceptScore W1820981194C78085059 @default.
- W1820981194 hasConceptScore W1820981194C90924648 @default.
- W1820981194 hasIssue "2B" @default.
- W1820981194 hasLocation W18209811941 @default.
- W1820981194 hasOpenAccess W1820981194 @default.
- W1820981194 hasPrimaryLocation W18209811941 @default.
- W1820981194 hasRelatedWork W1573769092 @default.
- W1820981194 hasRelatedWork W2008778169 @default.
- W1820981194 hasRelatedWork W2009348334 @default.
- W1820981194 hasRelatedWork W2052319471 @default.
- W1820981194 hasRelatedWork W2067411265 @default.